While summer may be the time of year most associated with itchy insect bites, winter can bring scratchy skin for a whole ...

Agency has seen explosion in disability claims for the treatment of ailments with seemingly few ties to combat ...

Zoryve cream gains FDA approval for treating mild to moderate atopic dermatitis in young children, offering a safe, ...

Roflumilast cream 0.05% is approved for children aged 2 to 5 with mild to moderate atopic dermatitis, offering a steroid-free ...

Countless veterans who deserve disability benefits are undermined by fraudulent claims. U.S. servicemembers who sustain injuries while putting their lives on the line for our country deserve generous ...

The Department of Veterans Affairs spends billions on dubious and even fraudulent disabilities benefits. Meanwhile, some ...

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere ...

This approval follows the recent FDA approval of ruxolitinib cream 1.5% (Opzelura), a topical JAK inhibitor, as a treatment ...

The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.

SHOPPERS have been told to check their bathrooms as more roll-on deodorants are removed from shelves. The safety notice links ...

Investing.com -- Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock gained 1.5% in Monday’s premarket trading after the U.S. Food and Drug Administration approved its ZORYVE cream for treating mild to ...

It’s finally fall, and as the crisp weather rolls in, many are rushing to get outside. As allergens fill the air, people ...